Avandia Revenues Sink Under Safety Attack
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of rosiglitazone were hit the hardest in the U.S., falling 31 percent, GSK reports days ahead of an FDA advisory committee meeting.
You may also be interested in...
Schering-Plough’s Vytorin “Permanently Broken,” Analyst Says
ENHANCE data prompts Avandia-like scramble.
Schering-Plough’s Vytorin “Permanently Broken,” Analyst Says
ENHANCE data prompts Avandia-like scramble.
GSK To Cut $1.5 Billion In Restructuring Initiative As Avandia Q3 Sales Plummet
U.S. Avandia sales fall 48 percent to $266 million; overall pharmaceutical sales were down 2 percent to $9.4 billion.